Predictive modeling of putamen dopamine in Parkinson disease: Relevance to prognosis, treatment, and prevention

<b>Background:</b> Depletion of putamen dopamine (DA) characterizes Parkinson disease (PD) and precedes the onset of motor symptoms by years. Increasing evidence implicates impaired vesicular sequestration and attenuated detoxification of the toxic catecholaldehyde 3,4-dihydroxyphenylacetaldehyde (DOPAL) in disease pathogenesis. We applied a mechanistic kinetic model to examine how perturbations in dopamine handling from DOPAL-induced autotoxicity affect the timing and trajectory of symptomatic PD. <b>Methods:</b> Using an icon-based application we constructed a model of intraneuronal dopamine synthesis, vesicular storage, leakage, metabolism, aldehyde detoxification, delayed toxicity, and a-synuclein modification. Model behavior was evaluated by internal consistency and concordance with empirical cellular, animal, imaging, and post-mortem neurochemical data. We examined predicted effects of genetic variants, acquired factors (e.g., stress, environmental exposures), and treatments on vesicular dopamine content across the lifespan. <b>Results:</b> Without imposing a pre-defined disease curve, the model generated a tri-phasic trajectory of vesicular dopamine loss-homeostasis, dyshomeostasis, and symptomatic decline-from delayed DOPAL-mediated toxicity, with progressive impairment of vesicular sequestration and other intra-neuronal processes. The model predicted that genetic decreases in vesicular uptake or aldehyde detoxification and increases in dopamine biosynthesis would shorten the time to the onset of symptomatic disease, whereas monoamine oxidase inhibition, levodopa, and anti-oxidant treatment applied early and in combination would be protective. Preclinical, multi-target interventions would delay or prevent crossing a symptomatic threshold within the modeled lifespan. <b>Conclusion:</b> Systems modeling across the lifespan predicts a tri-phasic decline in putamen dopamine stores in PD. The timing and combination of interventions may be decisive for delaying or preventing symptomatic disease.

Authors

Institutions

Publication Details

Journal
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Published
2026-03-28
DOI
https://doi.org/10.1152/ajpregu.00027.2026
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Predictive modeling of putamen dopamine in Parkinson disease: Relevance to prognosis, treatment, and prevention

David S. Goldstein
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Parkinson's Disease Mechanisms and Treatments
article

Predictive modeling of putamen dopamine in Parkinson disease: Relevance to prognosis, treatment, and prevention

David S. Goldstein
article en

Abstract

<b>Background:</b> Depletion of putamen dopamine (DA) characterizes Parkinson disease (PD) and precedes the onset of motor symptoms by years. Increasing evidence implicates impaired vesicular sequestration and attenuated detoxification of the toxic catecholaldehyde 3,4-dihydroxyphenylacetaldehyde (DOPAL) in disease pathogenesis. We applied a mechanistic kinetic model to examine how perturbations in dopamine handling from DOPAL-induced autotoxicity affect the timing and trajectory of symptomatic PD. <b>Methods:</b> Using an icon-based application we constructed a model of intraneuronal dopamine synthesis, vesicular storage, leakage, metabolism, aldehyde detoxification, delayed toxicity, and a-synuclein modification. Model behavior was evaluated by internal consistency and concordance with empirical cellular, animal, imaging, and post-mortem neurochemical data. We examined predicted effects of genetic variants, acquired factors (e.g., stress, environmental exposures), and treatments on vesicular dopamine content across the lifespan. <b>Results:</b> Without imposing a pre-defined disease curve, the model generated a tri-phasic trajectory of vesicular dopamine loss-homeostasis, dyshomeostasis, and symptomatic decline-from delayed DOPAL-mediated toxicity, with progressive impairment of vesicular sequestration and other intra-neuronal processes. The model predicted that genetic decreases in vesicular uptake or aldehyde detoxification and increases in dopamine biosynthesis would shorten the time to the onset of symptomatic disease, whereas monoamine oxidase inhibition, levodopa, and anti-oxidant treatment applied early and in combination would be protective. Preclinical, multi-target interventions would delay or prevent crossing a symptomatic threshold within the modeled lifespan. <b>Conclusion:</b> Systems modeling across the lifespan predicts a tri-phasic decline in putamen dopamine stores in PD. The timing and combination of interventions may be decisive for delaying or preventing symptomatic disease.

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
National Institutes of Health (US)
Openalex Percentile: Top 7%
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.